May 2010

No Stone Unturned

 

StoneLast month, I wrote about what I consider to be one of the most serious problems facing the life sciences in the age of genomics: the increasing polarization between those who do what they call “basic research” and those who do what is termed “translational research.” I argued that we have created this problem ourselves by accepting this divisive terminology and using it in everyday discourse. And, I asserted that we should abandon, forever, what I believe is an artificial and inaccurate distinction.

But, such a change raises a potential problem. Support for what we will no longer call basic research has, for quite some time, piggybacked on the support for what we will no longer call translational research, which was what scientific leaders presented to governments and laypeople as the raison d’etre for public support of biomedical research. Generally, they didn’t talk much about basic research at all, believing that the public wouldn’t understand it very well and therefore wouldn’t support it. They understood its importance themselves, so they paid for it, but they didn’t advertise it. National Institutes of Health Director Francis Collins’s now-famous remark that, “We’re not the National Institutes of Basic Sciences” is but one example of this mentality. If we now are to talk about all research using the same language, how do we justify the support of projects that don’t have an obvious clinical relevance and may never have one?

This problem is becoming more acute because we have oversold some big science projects to gain the huge financial support they require. The human genome sequencing effort, which really was a basic research project, was presented as a faster route to diagnosis and cures for a host of diseases, although it typically takes decades for research results to lead to clinical advances. Congress and the public, having bought the original sales pitch, now are asking, “So, where are the cures?”

Three articles in the March 17 issue of the Journal of the American Medical Association highlight this increasing impatience. They concern the war on cancer, a huge increase in both funding and responsibilities for the National Cancer Institute (one of the institutes that make up the NIH) that was started by President Richard Nixon in 1971. Ignoring the fact that the language of the legislation implied that cancer was one disease, which it most assuredly is not, and therefore should have one cure, which it most assuredly does not, the war has led to $100 billion dollars in research funding in the last 40 years, much of which has been spent on “basic” research in cellular and developmental biology. Now, as Susan Gapstur and Michael Thun point out (1), the cancer war has become a lightning rod, even for some who support its goals. “Frustration about the pace of its progress,” they write, “has led some critics to dismiss advances that have been made,” and “nearly 1 in 2 men and more than 1 in 3 women will be diagnosed with cancer given the current lifespan.” The annual cost to the United States of all cancers, as given by Elena Elkin and Peter Bach in an accompanying article (2), is more than $90 billion a year. (By comparison, the entire NIH budget is just a little more than $30 billion.) As more families face cancer-associated medical costs that can wipe out a lifetime of savings in a single year, the demand that scientists deliver on their promises is growing from a rumbling to a chorus.

Of course, there have been many successes in the cancer war, most of them resulting from fundamental discoveries about how cell growth is regulated and how cancer starts. Miracle drugs have turned testicular cancer and gastrointestinal stromal cancer and chronic myelogenous leukemia, to name but a few, into treatable diseases in many cases. But there are more than 100 different forms of cancer, and most of them still have no cure if the disease is not caught at its earliest stages. Faced with this reality, the instinct of many scientific administrators and researchers is to make even more promises and to push even harder for more applied research. Writing in the same issue of JAMA, John Niederhuber (3), the current director of the National Cancer Institute, does exactly that: “To realize a future of personalized medicine, the translation of genomic and functional biology discoveries into clinical practice is essential.”

So, you see what we’re up against. We should talk about research as a seamless whole, a continuum of effort that flows from fundamental discoveries with no obvious application inexorably to the prevention and treatment of human diseases. Yet, to justify it to the public, we have created a distinction that could ultimately tear the biomedical community asunder. How do we make people understand why it is in their best interest for us to do things that have no apparent connection to their concerns?

An old joke encapsulates the problem. A drunkard is looking for his lost car keys at night under a lamppost. A passer-by offers to help and asks exactly where he lost them. “Over there,” he replies, pointing off into the darkness. “But then, why are you looking for them here?” says the puzzled samaritan. The drunkard explains, “Because the light’s better here.”

NEXT PAGE 1 | 2

First Name:
Last Name:
Email:
Comment:


Comment on this item:
Rating:
Our comments are moderated. Maximum 1000 characters. We would appreciate it if you signed your name to your comment.


  


COMMENTS:

Kudos to our current President. I am glad he explained "translational research". I always thought it had something to do with protein synthesis. Just kidding. But that term is really not useful. We really need to educate the "funders" as President Petsko tries to do in this article. The article should be on every Copngresspersons's and Congressional Staffer's desks, especially those dealing with HEW. I now always read our Presidents article in ASBMB Today. There was a time I did not. He is doing a wonderful job.

 

5/4/2010--Maybe I've been lucky, but seems like I travel between the "basic" and "translational" villages a lot. We used the simple monosaccharide, mannose, to treat patients with a rare inherited glycosylation disorder (CDG-Ib), only to realize that the basic research on its metabolism was unfinished. Ticket in hand, headed back to "basic-ville". Hud Freeze, La Jolla CA

 

0 Comments

Page 1 of 1

found= true726